ArticleScientific reports2025
Zinc oxide nanoemulsions prevent kidney stone formation and protect renal function in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney stones have a high recurrence rate, with around 50% of patients encountering one within 10 years of treatment. Crud Cymbopogon Proximus (CP) was used in this work to develop a novel, eco-friendly, and non-toxic approach of ZnO nanoemulsions to assess the protective effects against ethylene glycol-induced renal stones and rat kidney tissue damage in male albino rats. ZnO@CP nanoemulsions were created using high-speed homogenization and the wet chemical precipitation technique. The properties of synthesized powder were characterized using ultraviolet (UV)–visible spectroscopy, Fourier transform infrared (FTIR), Dynamic light scattering (DLS) and Transmission electron microscopy (TEM). Animal studies were divided into six groups: normal control, positive control, standard control, CP, ZnONPs, and ZnO@CP NEs groups and euthanization occurred after 28 days after treatment. DLS and TEM showed a spherical ZnONPs and ZnO@CP NEs in the range of 71.55 nm and 145.8 nm. The nano-sized ZnONPs and ZnO@CP NEs exhibited the UV absorption peak at 345 and 370 nm, respectively. FTIR spectroscopy showed stretching vibrations at 4000 –500 cm−1. In addition, cell viability was significantly reduced in a dose-dependent manner in the study of cytotoxicity. Additionally, ZnO@CP NEs therapy showed significant effect on kidney biochemical indicators, including serum (creatinine, urea, and uric acid) and liver biomarkers (ALT and AST). ZnO@CP NEs groups provided a closer look at calcium oxalate crystals under a microscope, and more effectively supported kidney function. Histopathological results confirmed that the potential preventive and therapeutic ZnO@CP NEs inhibit kidney stones. In conclusion, ZnO@CP NEs treatment revealed renoprotective strong effect against ethylene glycol-induced renal stones and rat kidney tissue damage in male albino rats, probably via its antioxidant, anti-inflammatory and antiurolithiatic activity properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.